Free tool
FAERS Monitor: Anoro Ellipta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203975 or its brand name (Anoro Ellipta, Umeclidinium Bromide, Vilanterol Trifenatate). Reports on generic versions are filed under their own applications.
Reports
16,834
Serious
5,911
35% of reports
Hospitalization
3,054
Death reported
856
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea2,391
- wrong technique in device usage process1,681
- drug ineffective1,639
- product complaint1,219
- cough1,116
- product dose omission issue930
- pneumonia684
- chronic obstructive pulmonary disease637
- condition aggravated521
- drug dispensing error496
- off label use491
- death478
- drug dose omission472
- product use in unapproved indication458
- fatigue457
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 267 |
| 2015 | 1,005 |
| 2016 | 1,554 |
| 2017 | 1,660 |
| 2018 | 2,336 |
| 2019 | 2,296 |
| 2020 | 2,026 |
| 2021 | 1,290 |
| 2022 | 981 |
| 2023 | 947 |
| 2024 | 981 |
| 2025 | 926 |
| 2026 | 559 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product complaintSignal | 1,219 | 63.1 | 59.7 | 70,938 |
| wrong technique in device usage processSignal | 1,681 | 46.6 | 44.5 | 72,437 |
| drug dispensing errorSignal | 496 | 41.9 | 38.4 | 19,128 |
| chronic obstructive pulmonary diseaseSignal | 637 | 15.4 | 14.3 | 8,497 |
| dyspnoeaSignal | 2,391 | 5.3 | 5.1 | 8,521 |
| coughSignal | 1,116 | 5.0 | 4.7 | 3,588 |
| product dose omission issueSignal | 930 | 4.0 | 3.7 | 2,078 |
| drug dose omissionSignal | 472 | 3.6 | 3.3 | 877 |
| pneumoniaSignal | 684 | 2.6 | 2.5 | 706 |
| product use in unapproved indicationSignal | 458 | 2.3 | 2.1 | 343 |
| condition aggravatedSignal | 521 | 2.1 | 2.0 | 321 |
| drug ineffective | 1,639 | 1.6 | 1.5 | 345 |
| fatigue | 457 | 0.7 | 0.7 | 46 |
| off label use | 491 | 0.7 | 0.6 | 65 |
| death | 478 | 0.7 | 0.6 | 67 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.